Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT06204991 2025-08-24

ADP-TILIL7

Phase 1 Recruiting

10 enrolled

Dermatologic

Melanoma

NCT07063875 2025-07-14

SILVER

Phase 1/2 Recruiting

8 enrolled

Dermatologic

Uveal Melanoma

NCT05483491 2025-03-30

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Phase 1 Recruiting

30 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Lung Neoplasms, Stomach Neoplasms

NCT05141474 2024-11-07

NEXTGENTIL-ACT

Phase EARLY_PHASE1 Recruiting

10 enrolled

Tumor-Agnostic

Carcinoma

NCT03658785 2024-08-13

Immunotherapy for the Treatment of Advanced Solid Tumor

Phase 1/2 Recruiting

40 enrolled

Neoplasm Metastasis, Recurrence

NCT01704716 2020-10-23

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Phase 3 Recruiting

3,300 enrolled

CNS

Neuroblastoma

Clinical Trials

RIOT 4B

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

CIML NK Cells With Venetoclax for AML

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

TIL Therapy in cSCC and MCC

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

(RIOT 4A)

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers